1. Home
  2. WHD vs MIRM Comparison

WHD vs MIRM Comparison

Compare WHD & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WHD
  • MIRM
  • Stock Information
  • Founded
  • WHD 2011
  • MIRM 2018
  • Country
  • WHD United States
  • MIRM United States
  • Employees
  • WHD N/A
  • MIRM N/A
  • Industry
  • WHD Metal Fabrications
  • MIRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • WHD Industrials
  • MIRM Health Care
  • Exchange
  • WHD Nasdaq
  • MIRM Nasdaq
  • Market Cap
  • WHD 3.1B
  • MIRM 3.3B
  • IPO Year
  • WHD 2018
  • MIRM 2019
  • Fundamental
  • Price
  • WHD $42.36
  • MIRM $71.52
  • Analyst Decision
  • WHD Buy
  • MIRM Strong Buy
  • Analyst Count
  • WHD 4
  • MIRM 9
  • Target Price
  • WHD $50.75
  • MIRM $73.89
  • AVG Volume (30 Days)
  • WHD 766.4K
  • MIRM 751.2K
  • Earning Date
  • WHD 07-30-2025
  • MIRM 08-06-2025
  • Dividend Yield
  • WHD 1.32%
  • MIRM N/A
  • EPS Growth
  • WHD N/A
  • MIRM N/A
  • EPS
  • WHD 2.67
  • MIRM N/A
  • Revenue
  • WHD $1,119,196,000.00
  • MIRM $429,161,000.00
  • Revenue This Year
  • WHD $1.52
  • MIRM $36.76
  • Revenue Next Year
  • WHD $15.26
  • MIRM $17.48
  • P/E Ratio
  • WHD $14.75
  • MIRM N/A
  • Revenue Growth
  • WHD N/A
  • MIRM 62.33
  • 52 Week Low
  • WHD $33.80
  • MIRM $36.86
  • 52 Week High
  • WHD $70.01
  • MIRM $71.74
  • Technical
  • Relative Strength Index (RSI)
  • WHD 54.43
  • MIRM 79.29
  • Support Level
  • WHD $38.63
  • MIRM $64.76
  • Resistance Level
  • WHD $40.55
  • MIRM $69.27
  • Average True Range (ATR)
  • WHD 1.27
  • MIRM 3.25
  • MACD
  • WHD 0.22
  • MIRM 0.86
  • Stochastic Oscillator
  • WHD 97.93
  • MIRM 97.43

About WHD Cactus Inc.

Cactus Inc is engaged in the designing, manufacturing, and sale of wellheads and pressure control equipment. Its principal products include Cactus SafeDrill wellhead systems, conventional wellheads, and production valves among others. The company also provides mission-critical field services, including service crews to assist with the installation, maintenance, and safe handling of the wellhead and pressure control equipment, as well as repair services for equipment that it sells or rents. It sells or rents its products principally for onshore unconventional oil and gas wells that are utilized during the drilling, completion (including fracturing), and production. The company has two operating segments; Pressure Control, which generates key revenue and Spoolable Technologies.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: